Metabolomics to identify fingerprints of carotid atherosclerosis in nonobese metabolic dysfunction-associated fatty liver disease.
Congxiang ShaoLishu XuPingguang LeiWei WangShiting FengJunzhao YeBi-Hui ZhongPublished in: Journal of translational medicine (2023)
Diagnostic models combining different metabolites according to BMI categories could raise the accuracy of identifying subclinical CAS. Trial registration The study protocol was approved by the local ethics committee and all the participants have provided written informed consent (Approval number: [2014] No. 112, registered at the Chinese Clinical Trial Registry, ChiCTR-ChiCTR2000034197).
Keyphrases
- study protocol
- clinical trial
- drug administration
- randomized controlled trial
- phase ii
- crispr cas
- genome editing
- open label
- phase iii
- public health
- mass spectrometry
- body mass index
- ms ms
- double blind
- cardiovascular disease
- oxidative stress
- big data
- weight gain
- placebo controlled
- fatty acid
- global health
- type diabetes
- physical activity
- machine learning